Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech failure, 2002 -- Ignore unavailable to you. Want to Upgrade?

To: dalroi who wrote (56)	4/30/2002 12:55:35 PM
From: keokalani'nui	Respond to of 130

Ribozyme shares crumble after disappointing data (RZYM) By Michael Baron Ribozyme Pharmaceuticals (RZYM) is plummeting 87 cents, or 42 percent, to $1.20, after the Boulder, Colo., firm said that it has recently stopped dosing during its a phase two trial of its Heptazyme ribozyme treatment for hepatitis C in order to review an animal toxicity issue. Heptazyme is being developed to prevent replication of the hepatitis C virus. In addition, the company said that a trial to evaluate the potential of its Angiozyme treatment as a monotherapy for metastatic breast cancer didn't achieve a clinically meaningful response rate. Ribozyme said that, given what it's recently learned, it doesn't expect to see "clinically relevant" responses for anti-angiogenics when used as monotherapies.